Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Michael J, LaBarre"'
Publikováno v:
Drug Delivery, Vol 26, Iss 1, Pp 98-106 (2019)
ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degr
Externí odkaz:
https://doaj.org/article/db94eb4355944ba4a608ab317f5696f8
Autor:
Curtis B. Thompson, Daniel C. Maneval, Michael J. LaBarre, Darin M. Taverna, Daniel D. Von Hoff, Haiyong Han, Clifford J. Whatcott, Mark D. Pagel, Sheryl A. Garrovillo, Barbara Blouw, Sanna Rosengren, Ryan J. Osgood, Chunmei Zhao, Jessica A. Cowell, H. Michael Shepard, Xiaoming Li
AsPC-1 parental cells (AsPC-1-P) engineered to overexpress HAS3 (AsPC-1/HAS3, see Materials and Methods) produced more HA in the peritumoral matrix and the stroma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8848a82ee33c79fb2dbd4b4d9bfa5878
https://doi.org/10.1158/1078-0432.22470269.v1
https://doi.org/10.1158/1078-0432.22470269.v1
Autor:
Caglar Cekic, Ozgur Sahin, Christopher D. Thanos, Joel Linden, Silvia Deaglio, H. Michael Shepard, Xiaoming Li, Michael J. LaBarre, Lei Huang, Kim B. Phan, Qiping Zhao, Renee Clift, Hong Pei, Sara Serra, Pelin G. Ersan, Mertkaya Aras, Ozge Saatci, Jessica Cowell, Luz M. Londono, Lin Wang
Supplementary Table 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d72a8b0e03229bebd0a5ae110699f11
https://doi.org/10.1158/0008-5472.22428382.v1
https://doi.org/10.1158/0008-5472.22428382.v1
Autor:
Caglar Cekic, Ozgur Sahin, Christopher D. Thanos, Joel Linden, Silvia Deaglio, H. Michael Shepard, Xiaoming Li, Michael J. LaBarre, Lei Huang, Kim B. Phan, Qiping Zhao, Renee Clift, Hong Pei, Sara Serra, Pelin G. Ersan, Mertkaya Aras, Ozge Saatci, Jessica Cowell, Luz M. Londono, Lin Wang
Supplementary Figure S1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0253382f52d2980d9447dcdfb9263c9
https://doi.org/10.1158/0008-5472.22428394
https://doi.org/10.1158/0008-5472.22428394
Autor:
Curtis B. Thompson, Daniel C. Maneval, Michael J. LaBarre, Darin M. Taverna, Daniel D. Von Hoff, Haiyong Han, Clifford J. Whatcott, Mark D. Pagel, Sheryl A. Garrovillo, Barbara Blouw, Sanna Rosengren, Ryan J. Osgood, Chunmei Zhao, Jessica A. Cowell, H. Michael Shepard, Xiaoming Li
Purpose: The tumor microenvironment (TME) evolves to support tumor progression. One marker of more aggressive malignancy is hyaluronan (HA) accumulation. Here, we characterize biological and physical changes associated with HA-accumulating (HA-high)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c31d164a97d3bdde1c5c4fecf6f5286
https://doi.org/10.1158/1078-0432.c.6527495
https://doi.org/10.1158/1078-0432.c.6527495
Autor:
Caglar Cekic, Ozgur Sahin, Christopher D. Thanos, Joel Linden, Silvia Deaglio, H. Michael Shepard, Xiaoming Li, Michael J. LaBarre, Lei Huang, Kim B. Phan, Qiping Zhao, Renee Clift, Hong Pei, Sara Serra, Pelin G. Ersan, Mertkaya Aras, Ozge Saatci, Jessica Cowell, Luz M. Londono, Lin Wang
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c2abcb266f7c6f929463efb4bc5a20
https://doi.org/10.1158/0008-5472.c.6513007
https://doi.org/10.1158/0008-5472.c.6513007
Autor:
Marie A, Printz, Barry J, Sugarman, Rudolph D, Paladini, Michael C, Jorge, Yan, Wang, David W, Kang, Daniel C, Maneval, Michael J, LaBarre
Publikováno v:
The AAPS Journal. 24
Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd987b0d5a8918688ebd6fcb24885b1
https://doi.org/10.1208/s12248-022-00757-3
https://doi.org/10.1208/s12248-022-00757-3
Publikováno v:
Expert Opinion on Drug Delivery. 18:1673-1685
The glycosaminoglycan hyaluronan forms a gel-like substance, which presents a barrier to bulk fluid flow in the subcutaneous (SC) space, limiting SC drug delivery volume and administration rates. Recombinant human hyaluronidase PH20 (rHuPH20) acts lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a3a052337437e2b10c0a9b988904921
https://doi.org/10.1080/17425247.2021.1981286
https://doi.org/10.1080/17425247.2021.1981286
Autor:
Pelin Gülizar Ersan, Hong Pei, Joel Linden, Sara Serra, Kim Phan, Qiping Zhao, Caglar Cekic, Renee Clift, H. Michael Shepard, Lei Huang, Michael J. LaBarre, Mertkaya Aras, Christopher D. Thanos, Lin Wang, Ozgur Sahin, Jessica Cowell, Xiaoming Li, Silvia Deaglio, Luz Marina Londoño, Ozge Saatci
Publikováno v:
Cancer Research. 81:3319-3332
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a9c8945b30991ef06df0416d4ec6c3
https://doi.org/10.1158/0008-5472.can-21-0340
https://doi.org/10.1158/0008-5472.can-21-0340
Publikováno v:
Drug Design, Development and Therapy
Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1–2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses challenges for high-dose biologics, as these formulations may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251cfdc554c5c7313411677ed2c97d96
https://doi.org/10.2147/dddt.s287323
https://doi.org/10.2147/dddt.s287323